BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, Raine T, Parkes M; UK IBD BioResource Investigators., UK IBD Bioresource Investigators. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut 2021;70:677-86. [PMID: 33004550 DOI: 10.1136/gutjnl-2019-320185] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Lees CW, Irving PM, Beaugerie L. COVID-19 and IBD drugs: should we change anything at the moment? Gut 2021;70:632-4. [PMID: 33214164 DOI: 10.1136/gutjnl-2020-323247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
2 Jorissen C, Verstockt B, Schils N, Sabino J, Ferrante M, Vermeire S. Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. Scand J Gastroenterol 2021;:1-5. [PMID: 34399630 DOI: 10.1080/00365521.2021.1965207] [Reference Citation Analysis]
3 Wan F, Han H, Zhong R, Wang M, Tang S, Zhang S, Hou F, Yi B, Zhang H. Dihydroquercetin supplement alleviates colonic inflammation potentially through improved gut microbiota community in mice. Food Funct 2021;12:11420-34. [PMID: 34673859 DOI: 10.1039/d1fo01422f] [Reference Citation Analysis]
4 Verstockt B, Boets L, Sabino J, Vermeire S, Ferrante M. Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. Gut 2021;70:1416-8. [PMID: 32928916 DOI: 10.1136/gutjnl-2020-322646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rezazadeh Ardabili A, Jeuring S, Mujagic Z, Oostenbrug L, Romberg-Camps M, Jonkers D, van Bodegraven A, Pierik M. Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35794735 DOI: 10.1111/apt.17128] [Reference Citation Analysis]
6 Rönnblom A, Ljunggren Ö, Karlbom U. Complications and adverse effects related to surgical and medical treatment in patients with inflammatory bowel disease in a prospectively recruited population-based cohort. Scand J Gastroenterol 2021;:1-8. [PMID: 34369245 DOI: 10.1080/00365521.2021.1961309] [Reference Citation Analysis]
7 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
8 Macaluso FS, Orlando A, Papi C, Festa S, Pugliese D, Bonovas S, Pansieri C, Piovani D, Fiorino G, Fantini MC, Caprioli F, Daperno M, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)., Working panel., Review panel. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00137-2. [PMID: 35184989 DOI: 10.1016/j.dld.2022.01.127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kiszka-Kanowitz M, Theede K, Thomsen SB, Bjerrum JT, Brynskov J, Gottschalck IB, Akimenko E, Hilsted KL, Neumann A, Wildt S, Larsen L, Munk JK, Ibsen PH, Janjua HGR, Gluud LL, Mertz-Nielsen A. Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial. EClinicalMedicine 2022;45:101332. [PMID: 35274092 DOI: 10.1016/j.eclinm.2022.101332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
11 Mourad FH, Leong RW, Kariyawasam VC. Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction? European Journal of Gastroenterology & Hepatology 2021;33:e1106-e1106. [DOI: 10.1097/meg.0000000000002212] [Reference Citation Analysis]
12 Michalopoulos G, Karmiris K. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. Curr Res Pharmacol Drug Discov 2022;3:100071. [PMID: 34988432 DOI: 10.1016/j.crphar.2021.100071] [Reference Citation Analysis]
13 Wan F, Wang M, Zhong R, Chen L, Han H, Liu L, Zhao Y, Lv H, Hou F, Yi B, Zhang H. Supplementation With Chinese Medicinal Plant Extracts From Lonicera hypoglauca and Scutellaria baicalensis Mitigates Colonic Inflammation by Regulating Oxidative Stress and Gut Microbiota in a Colitis Mouse Model. Front Cell Infect Microbiol 2021;11:798052. [PMID: 35059326 DOI: 10.3389/fcimb.2021.798052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ranjan MK, Vuyyuru SK, Kante B, Kumar P, Mundhra SK, Golla R, Sharma R, Sahni P, Das P, Makharia G, Kedia S, Ahuja V. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease. Int J Colorectal Dis 2022. [PMID: 35835862 DOI: 10.1007/s00384-022-04216-5] [Reference Citation Analysis]